An Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of Cizutamig in Patients With Immunoglobulin A Nephropathy
Latest Information Update: 01 Sep 2025
At a glance
- Drugs Cizutamig (Primary)
- Indications IgA nephropathy
- Focus Adverse reactions
Most Recent Events
- 28 Aug 2025 New trial record